Marimed INC Form 4 insider transactions

Jon R Levine, President and CEO, a Director and 10% owner of Marimed Inc., reported multiple transactions in common stock on July 15, 2026.

Timothy Shaw, Chief Operating Officer of Marimed Inc., reported multiple transactions in common stock on July 15, 2026.

Ryan Crandall, Chief Commercial Officer of Marimed Inc., reported multiple transactions in common stock on July 15, 2026.

Mario Pinho, Chief Financial Officer of Marimed Inc., reported multiple transactions in common stock on July 15, 2026.

Eva M.D. Selhub, a Director of Marimed Inc., reported multiple transactions in common stock on July 15, 2026.

David R Allen, a Director of Marimed Inc., reported multiple transactions in common stock on July 15, 2026.

Edward J Gildea, a Director of Marimed Inc., reported multiple transactions in common stock on July 15, 2026.

MariMed Inc. Chief Commercial Officer Ryan Crandall reports transactions involving restricted stock units and common stock.

Director Eva Selhub acquired 75,000 shares of MariMed Inc. common stock through the vesting and conversion of restricted stock units.

Director Edward Gildea acquired 75,000 shares of MariMed Inc. common stock through the vesting and conversion of restricted stock units.

Director David R. Allen acquired 75,000 shares of MariMed Inc. common stock through the vesting and conversion of restricted stock units.

MariMed Inc. reports transactions by Chief Commercial Officer Ryan Crandall involving restricted stock units and common stock.

MariMed Inc. director Edward J. Gildea was granted 75,000 Restricted Stock Units (RSUs) on June 4, 2026, as part of the company's non-employee director compensation program.

MariMed Inc. director David R. Allen was granted 75,000 Restricted Stock Units (RSUs) on June 4, 2026, vesting in one year.

MariMed Inc. Director Eva Selhub acquired 75,000 Restricted Stock Units (RSUs) on June 4, 2026, as part of the company's non-employee director compensation program.

MariMed Inc. Chief Operating Officer Timothy Shaw reported transactions involving common stock and restricted stock units, including acquisitions and withholdings for tax purposes.

MariMed Inc. reports insider transactions by Director and President/CEO Jon R. Levine, detailing RSU vesting and share withholding for tax purposes.

MariMed Inc. Chief Commercial Officer Ryan Crandall reports transactions involving restricted stock units and common stock.

MariMed Inc. President and CEO Jon R. Levine reported a transaction involving the purchase of 40,000 common shares.

CEO Jon Levine acquired 75,000 shares of MariMed common stock through the vesting of restricted stock units.

MariMed Inc. Chief Operating Officer Timothy Shaw was granted 170,625 restricted stock units in lieu of a cash bonus.

MariMed Inc. Chief Commercial Officer Ryan Crandall was granted 131,250 restricted stock units in lieu of a cash bonus.

MariMed CFO Mario Pinho was granted 153,125 restricted stock units in lieu of a portion of his 2025 annual cash bonus.

MariMed Inc. President and CEO Jon Levine was granted 122,500 restricted stock units in lieu of a portion of his 2025 annual cash bonus.

Timothy Shaw, Chief Operating Officer of MariMed Inc., reported transactions involving common stock and restricted stock units.

MariMed Inc. reports insider transactions by President and CEO Jon R. Levine, involving restricted stock units and common stock.

Marimed Inc.'s Chief Commercial Officer, Ryan Crandall, reported the conversion of restricted stock units into common stock and subsequent tax-related share withholding.

Marimed Inc.'s Chief Operating Officer, Timothy Shaw, reported the acquisition of 65,000 common shares from RSU conversion and the disposition of 22,523 shares for tax withholding.

Marimed Inc.'s Chief Financial Officer, Mario Pinho, converted 49,995 Restricted Stock Units into common stock and sold 17,324 shares for tax obligations.

Marimed Inc.'s Chief Financial Officer, Mario Pinho, converted 53,571 Restricted Stock Units into common stock and disposed of 15,724 shares for tax purposes on December 31, 2025.